Optimal adjuvant chemotherapy and targeted therapy for early breast cancer—cyclin-dependent kinase 4 and 6 inhibitors: ASCO guideline rapid recommendation update

Optimal adjuvant chemotherapy and targeted therapy for early breast cancer—cyclin-dependent kinase 4 and 6 inhibitors: ASCO guideline rapid recommendation update - American Society of Clinical Oncology (ASCO)

ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and Appendix 2, online only).

Background: In 2020, ASCO published a guideline on the selection of optimal adjuvant chemotherapy and targeted therapy for breast cancer.1 This is a rapid recommendation update of that guideline that addresses, in turn, the adjuvant use of the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors abemaciclib and ribociclib in patients with stage II and III breast cancer.


Read full Guideline